Bracco updates HeartSee coronary flow capacity software with new diagnostic features
Bracco Diagnostics, a U.S. subsidiary of Bracco Imaging S.p.A., has made substantial updates to its popular HeartSee software for quantifying myocardial blood flow (MBF) in cardiac positron emission tomography (PET) imaging.
Clinicians have been using HeartSee to diagnose and treat coronary artery disease (CAD) since the technology was first introduced in 2018. These latest updates, set to roll out over time to all existing users, include new diagnostic features and improved user access.
What is new in HeartSee 4.0
Heart teams implementing HeartSee will now gain access to multiple new diagnostic features intended to improve the overall quality of its CAD evaluations. These include subendocardial ischemia measurements, relative stress flow assessments and immediate access to a patient’s ejection fraction data.
In addition, Bracco Diagnostics made improved user access a top priority with this update, expanding its field support team, physician training efforts and Windows 10/11 compatibility to ensure it will be easier than ever for hospitals and clinics to integrate HeartSee into their own imaging workflows.
‘A new standard’
“Bracco Diagnostics has been at the forefront of cardiac PET imaging for over three decades,” Derek Steptoe, senior manager of nuclear cardiology for Bracco, said in a prepared statement. “The latest updates to our HeartSee software represent a significant milestone for our company, as they not only enhance the usability of this diagnostic tool but also broaden access to critical heart health insights. These improvements underscore our dedication to supporting physicians in making informed decisions that improve patient outcomes. We believe the new features of HeartSee will set a new standard in cardiac care, helping to detect and treat CAD more effectively and efficiently than ever before.”
“Since HeartSee was introduced in 2018, it has been instrumental in helping physicians accurately identify the right patients for intervention, thereby improving treatment outcomes and reducing the need for invasive procedures like stents or surgery,” added Sergey Kachur, MD, a longtime HeartSee user and director of echocardiography and nuclear cardiology at Ascension Sacred Heart. “Our cardiac PET program was built with the express intention of implementing HeartSee because of its unique capabilities.”
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.